Tonghua Dongbao's gout drug shows promising phase IIa results

Tonghua Dongbao Pharmaceutical's (SSE:600867) subsidiary, Tonghua Dongbao Zixing (Hangzhou) Biomedical, has completed a Phase IIa clinical trial for its gout drug, THDBH151 tablets, achieving the primary endpoint. The trial results indicate that THDBH151 effectively lowers blood uric acid levels in gout patients with once-daily dosing, demonstrating a favorable dose-response relationship and safety profile. The study, which involved patients with a history of poor response to existing treatments, suggests THDBH151 offers a potentially more stable and sustained control of blood uric acid levels. As of the announcement date, the company has invested approximately CNY 10,349.76 million in the project. Tonghua Dongbao will now proceed with further research and development.